Tenderwize
Retour à la recherche

Non-exclusive rebate agreement for Filgrastim

GWQ ServicePlus AG·Düsseldorf, Germany·Deadline Nov 10, 2027 · 439 days left·Open·Supplies
Inscrivez-vous pour sauvegarder
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V mit dem Wirkstoff Filgrastim.

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

Submission is not electronic and the notice indicates postal submission; missing or late physical delivery could invali...

Important procurement documents are referenced on the portal but were not included in the provided extracted text, so f...

No procurement documents available

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Dec 2027
  • Supply of pharmaceutical products, specifically rebate agreements for Filgrastim.
  • Conclusion of non-exclusive rebate agreements under § 130a Abs. 8 SGB V.
Afficher le résumé complet

Open procedure notice for a pharmaceutical supply arrangement in Germany concerning non-exclusive rebate agreements for the active substance Filgrastim. The notice indicates a join-at-any-time model for interested pharmaceutical companies, with contract start planned for 2026-01-01 and a submission/mailing deadline for signed documents on 2025-12-10 to enable first notification on 2026-01-01. No contract value is stated. Submission is not electronic and appears to be postal. Procurement documents are referenced on the GWQ portal, but only the XML notice text was provided for analysis.

Risques

Submission is not electronic and the notice indicates postal submission; missing or late physical delivery could invali...

Important procurement documents are referenced on the portal but were not included in the provided extracted text, so f...

No procurement documents available

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Signed contract in duplicate.
  • Proof of marketing authorization via extract from the public part of the AMIce database.

Administrative

  • Signed self-declaration (Annex 3).

Acheteur

Localisation

Düsseldorf, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE258895210

Activité

Health

Lots (1)

LOT-0000

Non-exclusive rebate agreement for Filgrastim

Single lot for concluding non-exclusive rebate agreements under § 130a(8) SGB V for the active substance Filgrastim. The model is described as open to all interested pharmaceutical companies on equal terms during the contract term. The notice says participating sickness funds may vary by specialist lot, but only one lot is structured here and no separate lot breakdown is provided in the structured data.

SuppliesEU fundedElectronic submission

Localisation

DEA11, Germany

Durée

Dec 2025 - Dec 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Nov 10, 2027

Détails de la procédure

Date de publication
17 Nov 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
765198-2025

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30